TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 GROWING INCIDENCES OF CANCER AND RARE DISORDERS
4.2.2 INCREASING LAUNCH OF BIOSIMILARS
4.2.3 RISING HEALTHCARE COSTS
4.3 RESTRAINTS
4.3.1 REGULATORY AND APPROVAL BARRIERS
4.3.2 LIMITED REIMBURSEMENT AND MARKET ACCESS
4.4 OPPORTUNITY
4.4.1 EXPANSION IN EMERGING MARKETS
4.4.2 PARTNERSHIPS AND COLLABORATIONS
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON GLOBAL BIOSIMILAR MARKET
6 GLOBAL BIOSIMILAR MARKET, BY DRUG CLASS
6.1 OVERVIEW
6.2 MONOCLONAL ANTIBODIES
6.2.1 ADALIMUMAB
6.2.2 INFLIXIMAB
6.2.3 RITUXIMAB
6.2.4 BEVACIZUMAB
6.2.5 TRASTUZUMAB
6.2.6 USTEKINUMAB
6.2.7 TOCILIZUMAB
6.2.8 AFLIBERCEPT
6.2.9 DUPILUMAB
6.2.10 DENOSUMAB
6.2.11 OTHERS
6.3 INSULIN
6.4 GRANULOCYTE COLONY- STIMULATING FACTOR
6.5 ERYTHROPOIETIN
6.6 RECOMBINANT HUMAN GROWTH HORMONE
6.7 ETANERCEPT
6.8 FOLLITROPIN
6.9 TERIPARATIDE
6.10 ANTICOAGULANTS
6.11 OTHERS
7 GLOBAL BIOSIMILAR MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 ONCOLOGY
7.2.1 BREAST CANCER
7.2.2 LUNG CANCER
7.2.3 PROSTATE CANCER
7.2.4 LEUKEMIA
7.2.5 BLADDER CANCER
7.2.6 COLORECTAL CANCER
7.2.7 OTHERS
7.3 AUTOIMMUNE DISEASES
7.4 INFECTIOUS DISEASES
7.5 BLOOD DISORDERS
7.6 OTHERS
8 GLOBAL BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 SUBCUTANEOUS
8.3 INTRAVENOUS
9 GLOBAL BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 HOSPITAL PHARMACIES
9.3 RETAIL PHARMACIES
9.4 ONLINE PHARMACIES
9.5 SPECIALTY PHARMACIES
10 GLOBAL BIOSIMILAR MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.2.3 MEXICO
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UK
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 INDIA
10.4.3 JAPAN
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST AND AFRICA
10.5.2 SOUTH AMERICA
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, 2024
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT LAUNCH
11.6.2 PRODUCT APPROVAL
11.6.3 AGREEMENT/COLLABORATION/PARTNERSHIP
12 COMPANY PROFILE
12.1 ELI LILLY AND COMPANY
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 SAMSUNG BIOEPIS
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIES
12.4 AMGEN INC.
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 PFIZER INC.
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 NOVARTIS AG
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 BIOGEN
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIES
12.8 BIOCON
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 DR. REDDY’S LABORATORIES LTD.
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCT OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 FRESENIUS KABI USA, LLC.
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
12.11 KIDSWELL BIO CORPORATION
12.11.1 COMPANY OVERVIEW
12.11.2 FINANCIAL OVERVIEW
12.11.3 PRODUCT OFFERED
12.11.4 KEY DEVELOPMENTS
12.11.5 SWOT ANALYSIS
12.11.6 KEY STRATEGIES
DATA CITATIONS
13 DATA CITATIONS
13.1 DATA CITATIONS
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 GLOBAL BIOSIMILAR MARKET, BY DRUG CLASS, 2019–2035 (USD BILLION)
TABLE 3 GLOBAL BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY REGION, 2019–2035 (USD BILLION)
TABLE 4 GLOBAL BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2035 (USD BILLION)
TABLE 5 GLOBAL BIOSIMILAR MARKET, FOR ADALIMUMAB, BY REGION, 2019–2035 (USD BILLION)
TABLE 6 GLOBAL BIOSIMILAR MARKET, FOR INFLIXIMAB, BY REGION, 2019–2035 (USD BILLION)
TABLE 7 GLOBAL BIOSIMILAR MARKET, FOR RITUXIMAB, BY REGION, 2019–2035 (USD BILLION)
TABLE 8 GLOBAL BIOSIMILAR MARKET, FOR BEVACIZUMAB, BY REGION, 2019–2035 (USD BILLION)
TABLE 9 GLOBAL BIOSIMILAR MARKET, FOR TRASTUZUMAB, BY REGION, 2019–2035 (USD BILLION)
TABLE 10 GLOBAL BIOSIMILAR MARKET, FOR USTEKINUMAB, BY REGION, 2019–2035 (USD BILLION)
TABLE 11 GLOBAL BIOSIMILAR MARKET, FOR TOCILIZUMAB, BY REGION, 2019–2035 (USD BILLION)
TABLE 12 GLOBAL BIOSIMILAR MARKET, FOR AFLIBERCEPT, BY REGION, 2019–2035 (USD BILLION)
TABLE 13 GLOBAL BIOSIMILAR MARKET, FOR DUPILUMAB, BY REGION, 2019–2035 (USD BILLION)
TABLE 14 GLOBAL BIOSIMILAR MARKET, FOR DENOSUMAB, BY REGION, 2019–2035 (USD BILLION)
TABLE 15 GLOBAL BIOSIMILAR MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION)
TABLE 16 GLOBAL BIOSIMILAR MARKET, FOR INSULIN, BY REGION, 2019–2035 (USD BILLION)
TABLE 17 GLOBAL BIOSIMILAR MARKET, FOR GRANULOCYTE COLONY- STIMULATING FACTOR, BY REGION, 2019–2035 (USD BILLION)
TABLE 18 GLOBAL BIOSIMILAR MARKET, FOR ERYTHROPOIETIN, BY REGION, 2019–2035 (USD BILLION)
TABLE 19 GLOBAL BIOSIMILAR MARKET, FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2019–2035 (USD BILLION)
TABLE 20 GLOBAL BIOSIMILAR MARKET, FOR ETANERCEPT, BY REGION, 2019–2035 (USD BILLION)
TABLE 21 GLOBAL BIOSIMILAR MARKET, FOR FOLLITROPIN, BY REGION, 2019–2035 (USD BILLION)
TABLE 22 GLOBAL BIOSIMILAR MARKET, FOR TERIPARATIDE, BY REGION, 2019–2035 (USD BILLION)
TABLE 23 GLOBAL BIOSIMILAR MARKET, FOR ANTICOAGULANTS, BY REGION, 2019–2035 (USD BILLION)
TABLE 24 GLOBAL BIOSIMILAR MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION)
TABLE 25 GLOBAL BIOSIMILAR MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 26 GLOBAL BIOSIMILAR MARKET, FOR ONCOLOGY, BY REGION, 2019–2035 (USD BILLION)
TABLE 27 GLOBAL BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019–2035 (USD BILLION)
TABLE 28 GLOBAL BIOSIMILAR MARKET, FOR BREAST CANCER, BY REGION, 2019–2035 (USD BILLION)
TABLE 29 GLOBAL BIOSIMILAR MARKET, FOR LUNG CANCER, BY REGION, 2019–2035 (USD BILLION)
TABLE 30 GLOBAL BIOSIMILAR MARKET, FOR PROSTATE CANCER, BY REGION, 2019–2035 (USD BILLION)
TABLE 31 GLOBAL BIOSIMILAR MARKET, FOR LEUKEMIA, BY REGION, 2019–2035 (USD BILLION)
TABLE 32 GLOBAL BIOSIMILAR MARKET, FOR BLADDER CANCER, BY REGION, 2019–2035 (USD BILLION)
TABLE 33 GLOBAL BIOSIMILAR MARKET, FOR COLORECTAL CANCER, BY REGION, 2019–2035 (USD BILLION)
TABLE 34 GLOBAL BIOSIMILAR MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION)
TABLE 35 GLOBAL BIOSIMILAR MARKET, FOR AUTOIMMUNE DISEASES, BY REGION, 2019–2035 (USD BILLION)
TABLE 36 GLOBAL BIOSIMILAR MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2019–2035 (USD BILLION)
TABLE 37 GLOBAL BIOSIMILAR MARKET, FOR BLOOD DISORDERS, BY REGION, 2019–2035 (USD BILLION)
TABLE 38 GLOBAL BIOSIMILAR MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION)
TABLE 39 GLOBAL BIOSIMILAR MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 40 GLOBAL BIOSIMILAR MARKET, FOR SUBCUTANEOUS, BY REGION, 2019–2035 (USD BILLION)
TABLE 41 GLOBAL BIOSIMILAR MARKET, FOR INTRAVENOUS, BY REGION, 2019–2035 (USD BILLION)
TABLE 42 GLOBAL BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 43 GLOBAL BIOSIMILAR MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2019–2035 (USD BILLION)
TABLE 44 GLOBAL BIOSIMILAR MARKET, FOR RETAIL PHARMACIES, BY REGION, 2019–2035 (USD BILLION)
TABLE 45 GLOBAL BIOSIMILAR MARKET, FOR ONLINE PHARMACIES, BY REGION, 2019–2035 (USD BILLION)
TABLE 46 GLOBAL BIOSIMILAR MARKET, FOR SPECIALTY PHARMACIES, BY REGION, 2019–2035 (USD BILLION)
TABLE 47 GLOBAL BIOSIMILAR MARKET, BY REGION, 2019-2035 (USD BILLION)
TABLE 48 NORTH AMERICA BIOSIMILAR MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
TABLE 49 NORTH AMERICA BIOSIMILAR MARKET, BY DRUG CLASS, 2019-2035 (USD BILLION)
TABLE 50 NORTH AMERICA BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2035 (USD BILLION)
TABLE 51 NORTH AMERICA BIOSIMILAR MARKET, BY APPLICATION, 2019-2035 (USD BILLION)
TABLE 52 NORTH AMERICA BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019-2035 (USD BILLION)
TABLE 53 NORTH AMERICA BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 54 NORTH AMERICA BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 55 US BIOSIMILAR MARKET, BY DRUG CLASS, 2019-2035 (USD BILLION)
TABLE 56 US BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2035 (USD BILLION)
TABLE 57 US BIOSIMILAR MARKET, BY APPLICATION, 2019-2035 (USD BILLION)
TABLE 58 US BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019-2035 (USD BILLION)
TABLE 59 US BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 60 US BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 61 CANADA BIOSIMILAR MARKET, BY DRUG CLASS, 2019-2035 (USD BILLION)
TABLE 62 CANADA BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2035 (USD BILLION)
TABLE 63 CANADA BIOSIMILAR MARKET, BY APPLICATION, 2019-2035 (USD BILLION)
TABLE 64 CANADA BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019-2035 (USD BILLION)
TABLE 65 CANADA BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 66 CANADA BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 67 MEXICO BIOSIMILAR MARKET, BY DRUG CLASS, 2019-2035 (USD BILLION)
TABLE 68 MEXICO BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019-2035 (USD BILLION)
TABLE 69 MEXICO BIOSIMILAR MARKET, BY APPLICATION, 2019-2035 (USD BILLION)
TABLE 70 MEXICO BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019-2035 (USD BILLION)
TABLE 71 MEXICO BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 72 MEXICO BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 73 EUROPE BIOSIMILARS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
TABLE 74 EUROPE BIOSIMILARS MARKET, BY DRUG CLASS, 2019-2035 (USD BILLION)
TABLE 75 EUROPE BIOSIMILARS MARKET, FOR MONICLONAL ANTIBODIES, BY TYPE, 2019-2035 (USD BILLION)
TABLE 76 EUROPE BIOSIMILARS MARKET, BY APPLICATION, 2019-2035 (USD BILLION)
TABLE 77 EUROPE BIOSIMILARS MARKET, FOR ONCOLOGY, BY TYPE, 2019-2035 (USD BILLION)
TABLE 78 EUROPE BIOSIMILARS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 79 EUROPE BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 80 GERMANY BIOSIMILARS MARKET, BY DRUG CLASS, 2019-2035 (USD BILLION)
TABLE 81 GERMANY BIOSIMILARS MARKET, FOR MONICLONAL ANTIBODIES, BY TYPE, 2019-2035 (USD BILLION)
TABLE 82 GERMANY BIOSIMILARS MARKET, BY APPLICATION, 2019-2035 (USD BILLION)
TABLE 83 GERMANY BIOSIMILARS MARKET, FOR ONCOLOGY, BY TYPE, 2019-2035 (USD BILLION)
TABLE 84 GERMANY BIOSIMILARS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 85 GERMANY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 86 FRANCE BIOSIMILARS MARKET, BY DRUG CLASS, 2019-2035 (USD BILLION)
TABLE 87 FRANCE BIOSIMILARS MARKET, FOR MONICLONAL ANTIBODIES, BY TYPE, 2019-2035 (USD BILLION)
TABLE 88 FRANCE BIOSIMILARS MARKET, BY APPLICATION, 2019-2035 (USD BILLION)
TABLE 89 FRANCE BIOSIMILARS MARKET, FOR ONCOLOGY, BY TYPE, 2019-2035 (USD BILLION)
TABLE 90 FRANCE BIOSIMILARS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 91 FRANCE BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 92 UK BIOSIMILARS MARKET, BY DRUG CLASS, 2019-2035 (USD BILLION)
TABLE 93 UK BIOSIMILARS MARKET, FOR MONICLONAL ANTIBODIES, BY TYPE, 2019-2035 (USD BILLION)
TABLE 94 UK BIOSIMILARS MARKET, BY APPLICATION, 2019-2035 (USD BILLION)
TABLE 95 UK BIOSIMILARS MARKET, FOR ONCOLOGY, BY TYPE, 2019-2035 (USD BILLION)
TABLE 96 UK BIOSIMILARS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 97 UK BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 98 ITALY BIOSIMILARS MARKET, BY DRUG CLASS, 2019-2035 (USD BILLION)
TABLE 99 ITALY BIOSIMILARS MARKET, FOR MONICLONAL ANTIBODIES, BY TYPE, 2019-2035 (USD BILLION)
TABLE 100 ITALY BIOSIMILARS MARKET, BY APPLICATION, 2019-2035 (USD BILLION)
TABLE 101 ITALY BIOSIMILARS MARKET, FOR ONCOLOGY, BY TYPE, 2019-2035 (USD BILLION)
TABLE 102 ITALY BIOSIMILARS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 103 ITALY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 104 SPAIN BIOSIMILARS MARKET, BY DRUG CLASS, 2019-2035 (USD BILLION)
TABLE 105 SPAIN BIOSIMILARS MARKET, FOR MONICLONAL ANTIBODIES, BY TYPE, 2019-2035 (USD BILLION)
TABLE 106 SPAIN BIOSIMILARS MARKET, BY APPLICATION, 2019-2035 (USD BILLION)
TABLE 107 SPAIN BIOSIMILARS MARKET, FOR ONCOLOGY, BY TYPE, 2019-2035 (USD BILLION)
TABLE 108 SPAIN BIOSIMILARS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 109 SPAIN BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 110 REST OF EUROPE BIOSIMILARS MARKET, BY DRUG CLASS, 2019-2035 (USD BILLION)
TABLE 111 REST OF EUROPE BIOSIMILARS MARKET, FOR MONICLONAL ANTIBODIES, BY TYPE, 2019-2035 (USD BILLION)
TABLE 112 REST OF EUROPE BIOSIMILARS MARKET, BY APPLICATION, 2019-2035 (USD BILLION)
TABLE 113 REST OF EUROPE BIOSIMILARS MARKET, FOR ONCOLOGY, BY TYPE, 2019-2035 (USD BILLION)
TABLE 114 REST OF EUROPE BIOSIMILARS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 115 REST OF EUROPE BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 116 ASIA-PACIFIC: BIOSIMILAR MARKET, BY COUNTRY, 2019–2035 (USD BILLION)
TABLE 117 ASIA-PACIFIC: BIOSIMILAR MARKET, BY DRUG CLASS, 2019–2035 (USD BILLION)
TABLE 118 ASIA-PACIFIC: BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2035 (USD BILLION)
TABLE 119 ASIA-PACIFIC: BIOSIMILAR MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 120 ASIA-PACIFIC: BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019–2035 (USD BILLION)
TABLE 121 ASIA-PACIFIC: BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 122 ASIA-PACIFIC: BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 123 CHINA: BIOSIMILAR MARKET, BY DRUG CLASS, 2019–2035 (USD BILLION)
TABLE 124 CHINA: BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2035 (USD BILLION)
TABLE 125 CHINA: BIOSIMILAR MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 126 CHINA: BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019–2035 (USD BILLION)
TABLE 127 CHINA: BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 128 CHINA: BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 129 INDIA -PACIFIC: BIOSIMILAR MARKET, BY DRUG CLASS, 2019–2035 (USD BILLION)
TABLE 130 INDIA: BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2035 (USD BILLION)
TABLE 131 INDIA: BIOSIMILAR MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 132 INDIA: BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019–2035 (USD BILLION)
TABLE 133 INDIA: BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 134 INDIA: BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 135 JAPAN: BIOSIMILAR MARKET, BY DRUG CLASS, 2019–2035 (USD BILLION)
TABLE 136 JAPAN: BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2035 (USD BILLION)
TABLE 137 JAPAN: BIOSIMILAR MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 138 JAPAN: BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019–2035 (USD BILLION)
TABLE 139 JAPAN: BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 140 JAPAN: BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 141 AUSTRALIA: BIOSIMILAR MARKET, BY DRUG CLASS, 2019–2035 (USD BILLION)
TABLE 142 AUSTRALIA: BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2035 (USD BILLION)
TABLE 143 AUSTRALIA: BIOSIMILAR MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 144 AUSTRALIA: BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019–2035 (USD BILLION)
TABLE 145 AUSTRALIA: BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 146 AUSTRALIA: BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 147 SOUTH KOREA: BIOSIMILAR MARKET, BY DRUG CLASS, 2019–2035 (USD BILLION)
TABLE 148 SOUTH KOREA: BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2035 (USD BILLION)
TABLE 149 SOUTH KOREA: BIOSIMILAR MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 150 SOUTH KOREA: BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019–2035 (USD BILLION)
TABLE 151 SOUTH KOREA: BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 152 SOUTH KOREA: BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 153 REST OF ASIA-PACIFIC: BIOSIMILAR MARKET, BY DRUG CLASS, 2019–2035 (USD BILLION)
TABLE 154 REST OF ASIA-PACIFIC: BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2035 (USD BILLION)
TABLE 155 REST OF ASIA-PACIFIC: BIOSIMILAR MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 156 REST OF ASIA-PACIFIC: BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019–2035 (USD BILLION)
TABLE 157 REST OF ASIA-PACIFIC: BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 158 REST OF ASIA-PACIFIC: BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 159 REST OF THE WORLD: BIOSIMILAR MARKET, BY COUNTRY, 2019–2035 (USD BILLION)
TABLE 160 REST OF THE WORLD: BIOSIMILAR MARKET, BY DRUG CLASS, 2019–2035 (USD BILLION)
TABLE 161 REST OF THE WORLD: BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2035 (USD BILLION)
TABLE 162 REST OF THE WORLD: BIOSIMILAR MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 163 REST OF THE WORLD: BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019–2035 (USD BILLION)
TABLE 164 REST OF THE WORLD: BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 165 REST OF THE WORLD: BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 166 MIDDLE EAST AND AFRICA: BIOSIMILAR MARKET, BY DRUG CLASS, 2019–2035 (USD BILLION)
TABLE 167 MIDDLE EAST AND AFRICA: BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2035 (USD BILLION)
TABLE 168 MIDDLE EAST AND AFRICA: BIOSIMILAR MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 169 MIDDLE EAST AND AFRICA: BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019–2035 (USD BILLION)
TABLE 170 MIDDLE EAST AND AFRICA: BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 171 MIDDLE EAST AND AFRICA: BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 172 SOUTH AMERICA: BIOSIMILAR MARKET, BY DRUG CLASS, 2019–2035 (USD BILLION)
TABLE 173 SOUTH AMERICA: BIOSIMILAR MARKET, FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2035 (USD BILLION)
TABLE 174 SOUTH AMERICA: BIOSIMILAR MARKET, BY APPLICATION, 2019–2035 (USD BILLION)
TABLE 175 SOUTH AMERICA: BIOSIMILAR MARKET, FOR ONCOLOGY, BY TYPE, 2019–2035 (USD BILLION)
TABLE 176 SOUTH AMERICA: BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)
TABLE 177 SOUTH AMERICA: BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)
TABLE 178 PUBLIC PLAYERS STOCK SUMMARY
TABLE 179 PRODUCT LAUNCH
TABLE 180 PRODUCT APPROVAL
TABLE 181 AGREEMENT/COLLABORATION/PARTNERSHIP
TABLE 182 ELI LILLY AND COMPANY: PRODUCTS OFFERED
TABLE 183 ELI LILLY AND COMPANY: KEY DEVELOPMENTS
TABLE 184 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 185 TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS
TABLE 186 SAMSUNG BIOEPIS: PRODUCT OFFERED
TABLE 187 SAMSUNG BIOEPIS: KEY DEVELOPMENTS
TABLE 188 AMGEN INC.: PRODUCTS OFFERED
TABLE 189 AMGEN INC.: KEY DEVELOPMENTS
TABLE 190 PFIZER INC.: PRODUCTS OFFERED
TABLE 191 PFIZER INC.: KEY DEVELOPMENTS
TABLE 192 NOVARTIS AG: PRODUCTS OFFERED
TABLE 193 NOVARTIS AG: KEY DEVELOPMENTS
TABLE 194 BIOGEN: PRODUCTS OFFERED
TABLE 195 BIOGEN: KEY DEVELOPMENTS
TABLE 196 BIOCON: PRODUCTS OFFERED
TABLE 197 BIOCON: KEY DEVELOPMENTS
TABLE 198 DR. REDDY'S LABORATORIES LTD.: PRODUCTS OFFERED
TABLE 199 DR. REDDY LABORATORIES: KEY DEVELOPMENTS
TABLE 200 FRESENIUS KABI USA, LLC.: PRODUCT OFFERED
TABLE 201 FRESENIUS KABI USA, LLC.: KEY DEVELOPMENTS
TABLE 202 KIDSWELL BIO CORPORATION: PRODUCTS OFFERED
TABLE 203 PROCTER & GAMBLE: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 1 GLOBAL BIOSIMILARS MARKET: STRUCTURE
FIGURE 2 GLOBAL BIOSIMILAR MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035)
FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2035)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2024-2035)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL BIOSIMILAR MARKET
FIGURE 6 GLOBAL BIOSIMILAR MARKET, BY DRUG CLASS, SEGMENT ATTRACTIVENESS ANALYSIS
FIGURE 7 GLOBAL BIOSIMILAR MARKET, MONOCLONAL ANTIBODIES, BY TYPE SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD BILLION)
FIGURE 8 GLOBAL BIOSIMILAR MARKET, BY DRUG CLASS, 2024 & 2035 (USD BILLION)
FIGURE 9 GLOBAL BIOSIMILAR MARKET SHARE (%), BY DRUG CLASS, 2024
FIGURE 10 GLOBAL BIOSIMILAR MARKET, BY APPLICATION, SEGMENT ATTRACTIVENESS ANALYSIS
FIGURE 11 GLOBAL BIOSIMILAR MARKET, BY APPLICATION, 2024 & 2035 (USD BILLION)
FIGURE 12 GLOBAL BIOSIMILAR MARKET SHARE (%), BY APPLICATION, 2024
FIGURE 13 GLOBAL BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, SEGMENT ATTRACTIVENESS ANALYSIS
FIGURE 14 GLOBAL BIOSIMILAR MARKET, BY ROUTE OF ADMINISTRATION, 2024 & 2035 (USD BILLION)
FIGURE 15 GLOBAL BIOSIMILAR MARKET SHARE (%), BY APPLICATION, 2024
FIGURE 16 GLOBAL BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, SEGMENT ATTRACTIVENESS ANALYSIS
FIGURE 17 GLOBAL BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2024 & 2035 (USD BILLION)
FIGURE 18 GLOBAL BIOSIMILAR MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024
FIGURE 19 GLOBAL BIOSIMILAR MARKET, BY REGION, 2024 & 2035 (USD BILLION)
FIGURE 20 GLOBAL BIOSIMILAR MARKET SHARE (%), BY REGION, 2024
FIGURE 21 NORTH AMERICA MARKET ANALYSIS: BIOSIMILAR MARKET, 2019-2035 (USD BILLION)
FIGURE 22 NORTH AMERICA BIOSIMILAR MARKET, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 23 NORTH AMERICA BIOSIMILAR MARKET SHARE (%), BY COUNTRY, 2024
FIGURE 24 EUROPE MARKET ANALYSIS: BIOSIMILARS MARKET, 2019-2035 (USD BILLION)
FIGURE 25 EUROPE BIOSIMILARS MARKET, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 26 EUROPE BIOSIMILARS MARKET SHARE (%), BY COUNTRY, 2024
FIGURE 27 ASIA-PACIFIC: BIOSIMILAR MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 28 ASIA-PACIFIC: BIOSIMILAR MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 29 REST OF THE WORLD: BIOSIMILAR MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 30 REST OF THE WORLD: BIOSIMILAR MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 31 GLOBAL BIOSIMILAR MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024
FIGURE 32 COMPETITOR DASHBOARD: GLOBAL BIOSIMILAR MARKET
FIGURE 33 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 ELI LILLY AND COMPANY: SWOT ANALYSIS
FIGURE 35 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 37 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 AMGEN INC.: SWOT ANALYSIS
FIGURE 39 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 PFIZER INC.: SWOT ANALYSIS
FIGURE 41 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 BIOGEN: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 43 BIOCON: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 44 BIOCON.: SWOT ANALYSIS
FIGURE 45 DR. REDDY'S LABORATORIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 46 KIDSWELL BIO CORPORATION: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 47 KIDSWELL BIO CORPORATION: SWOT ANALYSIS
